Holzinger A - Search Results

1

Automated manufacturing and characterization of clinical grade autologous CD20 CAR T cells for the treatment of patients with stage III/IV melanoma.

Aleksandrova K, Leise J, Priesner C, Aktas M, Apel M, Assenmacher M, Bürger I, Richter A, Altefrohne P, Schubert C, Holzinger A, Barden M, Bezler V, von Bergwelt-Baildon M, Borchmann P, Goudeva L, Glienke W, Arseniev L, Esser R, Abken H, Koehl U. Aleksandrova K, et al. Among authors: holzinger a. Front Immunol. 2024 Sep 25;15:1328368. doi: 10.3389/fimmu.2024.1328368. eCollection 2024. Front Immunol. 2024. PMID: 39386211 Free PMC article. Clinical Trial.

2

The growing world of CAR T cell trials: a systematic review.

Holzinger A, Barden M, Abken H. Holzinger A, et al. Cancer Immunol Immunother. 2016 Dec;65(12):1433-1450. doi: 10.1007/s00262-016-1895-5. Epub 2016 Sep 9. Cancer Immunol Immunother. 2016. PMID: 27613725 Free PMC article. Review.

3

Advances and Challenges of CAR T Cells in Clinical Trials.

Holzinger A, Abken H. Holzinger A, et al. Recent Results Cancer Res. 2020;214:93-128. doi: 10.1007/978-3-030-23765-3_3. Recent Results Cancer Res. 2020. PMID: 31473850

4

Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells.

Holzinger A, Abken H. Holzinger A, et al. Pharmacology. 2022;107(9-10):446-463. doi: 10.1159/000525052. Epub 2022 Jun 13. Pharmacology. 2022. PMID: 35696994 Free article. Review.

5

CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation.

Barden M, Holzinger A, Velas L, Mezősi-Csaplár M, Szöőr Á, Vereb G, Schütz GJ, Hombach AA, Abken H. Barden M, et al. Among authors: holzinger a. Front Immunol. 2023 Feb 1;14:1110482. doi: 10.3389/fimmu.2023.1110482. eCollection 2023. Front Immunol. 2023. PMID: 36817444 Free PMC article.

6

The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.

Hombach AA, Holzinger A, Abken H. Hombach AA, et al. Among authors: holzinger a. Curr Mol Med. 2013 Aug;13(7):1079-88. doi: 10.2174/1566524011313070003. Curr Mol Med. 2013. PMID: 23116267 Review.

7

CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.

Holzinger A, Abken H. Holzinger A, et al. Cancer Immunol Immunother. 2017 Nov;66(11):1505-1507. doi: 10.1007/s00262-017-2045-4. Epub 2017 Jul 28. Cancer Immunol Immunother. 2017. PMID: 28755091 Free PMC article. No abstract available.

8

CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.

Köhl U, Arsenieva S, Holzinger A, Abken H. Köhl U, et al. Among authors: holzinger a. Hum Gene Ther. 2018 May;29(5):559-568. doi: 10.1089/hum.2017.254. Epub 2018 Apr 5. Hum Gene Ther. 2018. PMID: 29620951

9

CAR T Cells: A Snapshot on the Growing Options to Design a CAR.

Holzinger A, Abken H. Holzinger A, et al. Hemasphere. 2019 Feb 1;3(1):e172. doi: 10.1097/HS9.0000000000000172. eCollection 2019 Feb. Hemasphere. 2019. PMID: 31723811 Free PMC article. Review.

10

[Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].

Holzinger A, Abken H. Holzinger A, et al. Internist (Berl). 2021 Jun;62(6):583-588. doi: 10.1007/s00108-021-01040-x. Epub 2021 Apr 29. Internist (Berl). 2021. PMID: 33928413 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

349 results

Search Page

Filters